The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
- Citation:
- Leuk Lymphoma vol 54 (7) 1405-1410
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 2
- Parents:
- 354
- Children:
- None
- Pharmas:
- Grants:
- CA33601, CA77597, CA41287, U10 CA031946, CA77651, U10 CA033601, CA77440, (CA31946
- Corr. Author:
- Authors:
- Sonali M. Smith Heiko Schöder Jeffrey L. Johnson Sin-Ho Jung Nancy L. Bartlett Bruce D. Cheson
- Networks:
- CAPITAL, LAPS-IL057, LAPS-MO011, LAPS-NY016
- Study
- CALGB-50602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Hodgkin lymphoma, galiximab, CD80, clinical trial